Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 17, 2007

SynCo to Help Prosensa Advance its RNA-based Therapeutics for DMD

  • SynCo Bio Partners and Prosensa will collaborate in the formulation and fill of Prosensa’s RNA-based therapeutics for Duchenne muscular dystrophy (DMD).

    "SynCo is pleased to be working with Prosensa on this important clinical program for the life-saving treatment of DMD,” Pierre Warffemius, CEO of SynCo commented. “We aim to establish a long-term relationship with Prosensa to support their expanding portfolio of nucleic acid based therapeutics against neuromuscular disorders by providing high quality aseptic formulation and filling services."



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »